PhorMed has raised over $2.5 million, gained more than 4,100 total shareholders, and has over 8,800 followers. They have completed Phase 1 trials and are preparing for Phase 2 trials.
Organizations Involved
None
Founders
Prof. Richard L. Chang, Ben Chang, Carole A. Salvador
Company Description
PhorMed is a Biotech Company specializing in Gene Repair Therapy, particularly with their lead drug RP-323. They aim to treat various disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma, and Acute Respiratory Distress Syndrome caused by COVID-19.